Literature DB >> 31896090

Evaluating infusate parameters for direct drug delivery to the brainstem: a comparative study of convection-enhanced delivery versus osmotic pump delivery.

Julian S Rechberger1, Erica A Power1,2, Victor M Lu1, Liang Zhang1, Jann N Sarkaria3, David J Daniels1,4.   

Abstract

OBJECTIVE: Convection-enhanced delivery (CED) and osmotic pump delivery both have been promoted as promising techniques to deliver drugs to pediatric diffuse intrinsic pontine gliomas (DIPGs). Correspondingly, the aim of this study was to understand how infusate molecular weight (MW), duration of delivery, and mechanism of delivery (CED or osmotic pump) affect volume of distribution (Vd) in the brainstem, to better inform drug selection and delivery in future DIPG investigations.
METHODS: A series of in vivo experiments were conducted using rat models. CED and osmotic pump delivery systems were surgically implanted in the brainstem, and different MW fluorescent dextran beads were infused either once (acute) or daily for 5 days (chronic) in a volume infused (Vi). Brainstems were harvested after the last infusion, and Vd was quantified using serial sectioning and fluorescence imaging.
RESULTS: Fluorescence imaging showed infusate uptake within the brainstem for both systems without complication. A significant inverse relationship was observed between infusate MW and Vd in all settings, which was distinctly exponential in nature in the setting of acute delivery across the 570-Da to 150-kDa range. Chronic duration and CED technique resulted in significantly greater Vd compared to acute duration or osmotic pump delivery, respectively. When accounting for Vi, acute infusion yielded significantly greater Vd/Vi than chronic infusion. The distribution in CED versus osmotic pump delivery was significantly affected by infusate MW at higher weights.
CONCLUSIONS: Here the authors demonstrate that infusate MW, duration of infusion, and infusion mechanism all impact the Vd of an infused agent and should be considered when selecting drugs and infusion parameters for novel investigations to treat DIPGs.

Entities:  

Keywords:  BBB = blood-brain barrier; BLI = bioluminescence imaging; CED; CED = convection-enhanced delivery; DIPG; DIPG = diffuse intrinsic pontine glioma; FITC = fluorescein isothiocyanate; MW = molecular weight; PDX = patient-derived xenograft; Vd = volume of distribution; Vi = volume infused; brainstem; convection-enhanced delivery; diffuse intrinsic pontine glioma; molecular weight; osmotic pump; volume of distribution

Mesh:

Year:  2020        PMID: 31896090      PMCID: PMC7371267          DOI: 10.3171/2019.10.FOCUS19703

Source DB:  PubMed          Journal:  Neurosurg Focus        ISSN: 1092-0684            Impact factor:   4.047


  32 in total

1.  Principles of the design and operation of generic osmotic pumps for the delivery of semisolid or liquid drug formulations.

Authors:  F Theeuwes; S I Yum
Journal:  Ann Biomed Eng       Date:  1976-12       Impact factor: 3.934

2.  Convection enhanced delivery of carmustine to the murine brainstem: a feasibility study.

Authors:  A Charlotte P Sewing; Viola Caretti; Tonny Lagerweij; Pepijn Schellen; Marc H A Jansen; Dannis G van Vuurden; Sander Idema; Carla F M Molthoff; W Peter Vandertop; Gertjan J L Kaspers; David P Noske; Esther Hulleman
Journal:  J Neurosci Methods       Date:  2014-09-27       Impact factor: 2.390

Review 3.  Reirradiation for diffuse intrinsic pontine glioma: a systematic review and meta-analysis.

Authors:  Victor M Lu; John P Welby; Anita Mahajan; Nadia N Laack; David J Daniels
Journal:  Childs Nerv Syst       Date:  2019-03-16       Impact factor: 1.475

4.  Real-Time, in Vivo Correlation of Molecular Structure with Drug Distribution in the Brain Striatum Following Convection Enhanced Delivery.

Authors:  Umberto Tosi; Harikrishna Kommidi; Vanessa Bellat; Christopher S Marnell; Hua Guo; Oluwaseyi Adeuyan; Melanie E Schweitzer; Nandi Chen; Taojunfeng Su; Guoan Zhang; Uday B Maachani; David J Pisapia; Benedict Law; Mark M Souweidane; Richard Ting
Journal:  ACS Chem Neurosci       Date:  2019-03-06       Impact factor: 4.418

Review 5.  The 100 Most-Cited Articles About Convection-Enhanced Delivery to the Brain: A Bibliometric Analysis.

Authors:  Victor M Lu; Julian S Rechberger; Benjamin T Himes; David J Daniels
Journal:  World Neurosurg       Date:  2019-05-29       Impact factor: 2.104

Review 6.  Convection-Enhanced Delivery.

Authors:  A M Mehta; A M Sonabend; J N Bruce
Journal:  Neurotherapeutics       Date:  2017-04       Impact factor: 7.620

7.  Convection-enhanced delivery for diffuse intrinsic pontine glioma: a single-centre, dose-escalation, phase 1 trial.

Authors:  Mark M Souweidane; Kim Kramer; Neeta Pandit-Taskar; Zhiping Zhou; Sofia Haque; Pat Zanzonico; Jorge A Carrasquillo; Serge K Lyashchenko; Sunitha B Thakur; Maria Donzelli; Ryan S Turner; Jason S Lewis; Nai-Kong V Cheung; Steven M Larson; Ira J Dunkel
Journal:  Lancet Oncol       Date:  2018-06-18       Impact factor: 41.316

8.  Toxicity evaluation of convection-enhanced delivery of small-molecule kinase inhibitors in naïve mouse brainstem.

Authors:  Zhiping Zhou; Sharon L Ho; Ranjodh Singh; David J Pisapia; Mark M Souweidane
Journal:  Childs Nerv Syst       Date:  2015-02-25       Impact factor: 1.475

Review 9.  Developing chemotherapy for diffuse pontine intrinsic gliomas (DIPG).

Authors:  Ho-Shin Gwak; Hyeon Jin Park
Journal:  Crit Rev Oncol Hematol       Date:  2017-10-31       Impact factor: 6.312

10.  Histone H3F3A and HIST1H3B K27M mutations define two subgroups of diffuse intrinsic pontine gliomas with different prognosis and phenotypes.

Authors:  David Castel; Cathy Philippe; Raphaël Calmon; Ludivine Le Dret; Nathalène Truffaux; Nathalie Boddaert; Mélanie Pagès; Kathryn R Taylor; Patrick Saulnier; Ludovic Lacroix; Alan Mackay; Chris Jones; Christian Sainte-Rose; Thomas Blauwblomme; Felipe Andreiuolo; Stephanie Puget; Jacques Grill; Pascale Varlet; Marie-Anne Debily
Journal:  Acta Neuropathol       Date:  2015-09-23       Impact factor: 17.088

View more
  4 in total

1.  IL-13Rα2 Status Predicts GB-13 (IL13.E13K-PE4E) Efficacy in High-Grade Glioma.

Authors:  Julian S Rechberger; Kendra A Porath; Liang Zhang; Cody L Nesvick; Randy S Schrecengost; Jann N Sarkaria; David J Daniels
Journal:  Pharmaceutics       Date:  2022-04-24       Impact factor: 6.525

Review 2.  Convection Enhanced Delivery in the Setting of High-Grade Gliomas.

Authors:  Chibueze D Nwagwu; Amanda V Immidisetti; Michael Y Jiang; Oluwasegun Adeagbo; David C Adamson; Anne-Marie Carbonell
Journal:  Pharmaceutics       Date:  2021-04-15       Impact factor: 6.321

Review 3.  Addressing BBB Heterogeneity: A New Paradigm for Drug Delivery to Brain Tumors.

Authors:  Jessica I Griffith; Sneha Rathi; Wenqiu Zhang; Wenjuan Zhang; Lester R Drewes; Jann N Sarkaria; William F Elmquist
Journal:  Pharmaceutics       Date:  2020-12-11       Impact factor: 6.321

4.  Convection enhanced delivery of EGFR targeting antibody-drug conjugates Serclutamab talirine and Depatux-M in glioblastoma patient-derived xenografts.

Authors:  Kendra A Porath; Michael S Regan; Jessica I Griffith; Sonia Jain; Sylwia A Stopka; Danielle M Burgenske; Katrina K Bakken; Brett L Carlson; Paul A Decker; Rachael A Vaubel; Sonja Dragojevic; Ann C Mladek; Margaret A Connors; Zeng Hu; Lihong He; Gaspar J Kitange; Shiv K Gupta; Thomas M Feldsien; Didier R Lefebvre; Nathalie Y R Agar; Jeanette E Eckel-Passow; Edward B Reilly; William F Elmquist; Jann N Sarkaria
Journal:  Neurooncol Adv       Date:  2022-08-24
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.